- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Eye on Pharma: JHL Biotech to Begin Phase 3 Trial of Biosimilar Trastuzumab
This week, JHL Biotech announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has granted the company positive scientific advice to begin a phase 3 clinical trial of its proposed trastuzumab biosimilar, JHL1188.
This week, JHL Biotech announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted the company positive scientific advice to begin a phase 3 clinical trial of its proposed trastuzumab biosimilar, JHL1188.
The potential biosimilar will be referenced on Herceptin, a monoclonal antibody approved for the treatment of HER2-positive breast cancer, metastatic gastric cancer, and gastroesophageal junction adenocarcinoma.
Click here to see a full list of US- and EU-approved trastuzumab biosimilars.
In the positive scientific advice sent by the EMA, the regulator agreed with the development approach of the potential biosimilar as well as the phase 3 clinical study design and the clinical development proposal. Assuming the trial is completed successfully, the results will be acceptable for submission of a Marketing Authorization Application.
This is just the latest update in clinical trials underway by JHL, as last month it announced that it had received positive scientific advice from the EMA's CHMP in regard to its potential rituximab biosimilar, JHL1101. Additionally, JHL also received a Clinical Trial Permit from the Center for Drug Evaluation of the State Drug Administration of China to initiate the same global phase 3 study of JHL1101. JHL plans to launch the trial in China, Europe, and other countries in the coming months.
The market for trastuzumab biosimilars is becoming more competitive, with 4 biosimilar products—Ontruzant, Herzuma, Kanjinti, and Trazimera—licensed in the European Union, and 1-Ogivri—licensed in the United States.
From Amjevita to Zarxio: A Decade of US Biosimilar Approvals
March 6th 2025Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 originators—though the journey has been anything but smooth, with adoption facing hurdles along the way.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
The Banking of Biosimilars: Insights From a Leading Health Economist
February 4th 2025Biosimilars have the potential to reduce health care costs and expand patient access, but economic and policy barriers affect adoption, explored James D. Chambers, PhD, MPharm, MSc, associate professor at the Tufts Medical Center Institute for Clinical Research and Health Policy Studies, in an interview.
